Going Concern Warning, Material Weakness in Controls, and Recurring Losses Highlight Financial Distress

summarizeSummary

The company issued a going concern warning, disclosed material weaknesses in internal controls, and reported recurring losses with negative operating cash flow, signaling severe financial and governance challenges.

check_boxKey Events

• Going Concern Warning Issued

  Management and auditors expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses, an accumulated deficit of $854,046, and negative working capital of $4,194,320 as of December 31, 2025.

• Material Weakness in Internal Controls

  The company identified a material weakness in its disclosure controls and procedures, citing a lack of sufficient financial reporting and accounting personnel with U.S. GAAP and SEC reporting knowledge, and an incomplete accounting policies manual.

• Negative Operating Cash Flow

  Operating cash flow shifted from an inflow of $312,006 in 2024 to an outflow of $35,845 in 2025, indicating increased cash burn from core operations.

• Multiple Auditor Changes

  The company changed its independent registered public accounting firm twice in 2024-2025, dismissing TPS Thayer, LLC and KCCW Accountancy Corp. before appointing YCM CPA INC. No disagreements were reported.

auto_awesomeAnalysis

Cordyceps Sunshine Biotech Holdings Co., Ltd. faces substantial doubt about its ability to continue as a going concern, as indicated by recurring losses, an accumulated deficit of $854,046, and negative working capital of $4,194,320 as of December 31, 2025. The company also reported a material weakness in its internal controls over financial reporting due to insufficient U.S. GAAP and SEC reporting expertise and a lack of comprehensive accounting policies. Furthermore, the company changed its independent registered public accounting firm twice in 2024-2025, which, while not citing disagreements, raises governance concerns. Operating cash flow turned negative in 2025, moving from an inflow of $312,006 in 2024 to an outflow of $35,845. These factors collectively point to significant financial and operational challenges.